These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34151801)

  • 21. No association of salivary total tau concentration with Alzheimer's disease.
    Ashton NJ; Ide M; Schöll M; Blennow K; Lovestone S; Hye A; Zetterberg H
    Neurobiol Aging; 2018 Oct; 70():125-127. PubMed ID: 30007161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease.
    Llano DA; Devanarayan V; Simon AJ;
    Alzheimer Dis Assoc Disord; 2013; 27(3):233-43. PubMed ID: 23023094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic plasma protein panel for Aβ deposition in the brain in Alzheimer's disease.
    Park JC; Han SH; Lee H; Jeong H; Byun MS; Bae J; Kim H; Lee DY; Yi D; Shin SA; Kim YK; Hwang D; Lee SW; Mook-Jung I
    Prog Neurobiol; 2019 Dec; 183():101690. PubMed ID: 31605717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study.
    Costa AC; Joaquim HPG; Forlenza OV; Gattaz WF; Talib LL
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):483-488. PubMed ID: 31218445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in metabolic pathways and networks in Alzheimer's disease.
    Kaddurah-Daouk R; Zhu H; Sharma S; Bogdanov M; Rozen SG; Matson W; Oki NO; Motsinger-Reif AA; Churchill E; Lei Z; Appleby D; Kling MA; Trojanowski JQ; Doraiswamy PM; Arnold SE;
    Transl Psychiatry; 2013 Apr; 3(4):e244. PubMed ID: 23571809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
    Johnstone D; Milward EA; Berretta R; Moscato P;
    PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early diagnosis of mild cognitive impairment and Alzheimer's with event-related potentials and event-related desynchronization in N-back working memory tasks.
    Fraga FJ; Mamani GQ; Johns E; Tavares G; Falk TH; Phillips NA
    Comput Methods Programs Biomed; 2018 Oct; 164():1-13. PubMed ID: 30195417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
    Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M
    PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
    Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z;
    Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.
    Han P; Caselli RJ; Baxter L; Serrano G; Yin J; Beach TG; Reiman EM; Shi J
    JAMA Neurol; 2015 Mar; 72(3):333-9. PubMed ID: 25599520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer's Disease or Mild Cognitive Impairment.
    Chen Y; Yan H; Han Z; Bi Y; Chen H; Liu J; Wu M; Wang Y; Zhang Y
    Curr Alzheimer Res; 2016; 13(3):234-42. PubMed ID: 26906355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting conversion from mild cognitive impairment to Alzheimer's disease using brain
    Mitolo M; Stanzani-Maserati M; Capellari S; Testa C; Rucci P; Poda R; Oppi F; Gallassi R; Sambati L; Rizzo G; Parchi P; Evangelisti S; Talozzi L; Tonon C; Lodi R; Liguori R
    Neuroimage Clin; 2019; 23():101843. PubMed ID: 31071594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development.
    Peña-Bautista C; Baquero M; Vento M; Cháfer-Pericás C
    Curr Neuropharmacol; 2019; 17(7):630-647. PubMed ID: 30255758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy and Psychometric Properties of the Brazilian Version of the Montreal Cognitive Assessment as a Brief Screening Tool for Mild Cognitive Impairment and Alzheimer's Disease in the Initial Stages in the Elderly.
    Pinto TCC; Machado L; Costa MLG; Santos MSP; Bulgacov TM; Rolim APP; Silva GA; Rodrigues-Júnior AL; Sougey EB; Ximenes RCC
    Dement Geriatr Cogn Disord; 2019; 47(4-6):366-374. PubMed ID: 31466064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease.
    Greenberg N; Grassano A; Thambisetty M; Lovestone S; Legido-Quigley C
    Electrophoresis; 2009 Apr; 30(7):1235-9. PubMed ID: 19288586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.